ArticleGels (Basel, Switzerland)2026
A New Cardiac Decellularized Extracellular Matrix (dECM)-Based Hydrogel: From Its Development with a Standardized Myocardial Decellularization Procedure to In Vitro Model Applications.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Injectable bioactive hydrogels as pharmacological drug delivery platforms for post-myocardial infarction cardiac repair: therapeutic cargo engineering, stimuli-responsive release mechanisms, and translational perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Cardiovascular diseases remain the leading cause of mortality worldwide, underscoring the urgent need for reliable in vitro models that recapitulate the complexity of the native myocardium. Conventional two-dimensional (2D) cultures lack structural and biochemical complexity, whereas in vivo models are costly, raise ethical concerns, and have poor translational potential. In this study, we developed a novel hydrogel scaffold derived from decellularized porcine ventricular myocardium (dECM). A newly optimized decellularization strategy effectively removed cellular and nuclear components while preserving essential extracellular matrix proteins. The dECM-based hydrogel exhibited reproducible self-crosslinking, gelation kinetics, and stability. Cytocompatibility assays using human bone marrow-derived mesenchymal stem cells demonstrated excellent viability and proliferation upon contact with the biomaterial. Multidimensional hydrogel applications (2.5D and 3D) in vitro revealed higher cell densities than those observed under 2D conditions. Moreover, using human umbilical vein endothelial cells, the dECM-based hydrogel proved to be a valid tool for fabricating cardiovascular in vitro models. As such, this cardiac dECM-based hydrogel is a structurally preserved, biocompatible platform that supports both short- and long-term cell culture. The scaffold has the potential to serve promising applications in cardiac tissue engineering, disease modeling, and cardiotoxicity screening by offering a closer mimicry of the native myocardial environment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.